Ligand Pharmaceuticals
LGND
233 hedge funds and large institutions have $2.51B invested in Ligand Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 86 increasing their positions, 77 reducing their positions, and 12 closing their positions.
350% more funds holding in top 10
Funds holding in top 10: 2 → 9 (+7)
258% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 12
29% more capital invested
Capital invested by funds: $1.95B → $2.51B (+$559M)
15% more funds holding
Funds holding: 203 → 233 (+30)
12% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 77
3% less call options, than puts
Call options by funds: $3.65M | Put options by funds: $3.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$31.3M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$14.6M |
| 3 |
Renaissance Technologies
New York
|
+$10.1M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$7.61M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$28.7M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$21M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$16.7M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$7.37M |
| 5 |
Bank of New York Mellon
New York
|
-$6.71M |
LGND Hedge Fund Activity: Q4 2015 in Review
233 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2015, worth a combined $2.51B — up 29% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new LGND positions and 12 closed out — a net gain of 31 holders — while 86 added to existing stakes and 77 trimmed.
The largest buyer was Wells Fargo, adding an estimated $31.3M. The largest seller was RS Investment Management, cutting an estimated $28.7M.
- 233 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2015, up from 203 in Q3 2015.
- Funds reported $2.51B of Ligand Pharmaceuticals stock for Q4 2015, up 29% quarter-over-quarter.
- 43 funds opened new Ligand Pharmaceuticals positions in Q4 2015 and 12 closed out, a net change of +31 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2015 was Wells Fargo, an estimated $31.3M added.
- The largest Ligand Pharmaceuticals seller in Q4 2015 was RS Investment Management, an estimated $28.7M sold.
Based on aggregated 13F filings for Q4 2015.